{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.9","value":"89.6"},{"groupId":"OG001","spread":"13.4","value":"89.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2338"},{"groupId":"OG001","value":"2342"}],"units":"Participants"}],"title":"Baseline: Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.2","value":"-10.7"},{"groupId":"OG001","spread":"17.7","value":"-10.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2077"},{"groupId":"OG001","value":"2115"}],"units":"Participants"}],"title":"Change at Week 13: Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.5","value":"-4.6"},{"groupId":"OG001","spread":"14.5","value":"-4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2052"},{"groupId":"OG001","value":"2078"}],"units":"Participants"}],"title":"Change at Week 25: Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.7","value":"-4.1"},{"groupId":"OG001","spread":"14.9","value":"-3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2262"},{"groupId":"OG001","value":"2287"}],"units":"Participants"}],"title":"Change at EOT: Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.5","value":"-0.9"},{"groupId":"OG001","spread":"14.5","value":"-0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1918"},{"groupId":"OG001","value":"1925"}],"units":"Participants"}],"title":"Change at FU Month 18: Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.8","value":"-0.4"},{"groupId":"OG001","spread":"14.5","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1867"},{"groupId":"OG001","value":"1875"}],"units":"Participants"}],"title":"Change at FU Month 24: Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.1","value":"-0.3"},{"groupId":"OG001","spread":"13.9","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1820"},{"groupId":"OG001","value":"1792"}],"units":"Participants"}],"title":"Change at FU Month 36: Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.7","value":"79.8"},{"groupId":"OG001","spread":"25.2","value":"79.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2334"},{"groupId":"OG001","value":"2337"}],"units":"Participants"}],"title":"Baseline: Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.6","value":"-8.0"},{"groupId":"OG001","spread":"29.5","value":"-8.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2075"},{"groupId":"OG001","value":"2111"}],"units":"Participants"}],"title":"Change at Week 13: Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.4","value":"-0.7"},{"groupId":"OG001","spread":"27.8","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2073"}],"units":"Participants"}],"title":"Change at Week 25: Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.8","value":"0.4"},{"groupId":"OG001","spread":"28.1","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2281"}],"units":"Participants"}],"title":"Change at EOT: Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.5","value":"6.1"},{"groupId":"OG001","spread":"28.9","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1916"},{"groupId":"OG001","value":"1921"}],"units":"Participants"}],"title":"Change at FU Month 18: Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.8","value":"7.3"},{"groupId":"OG001","spread":"28.2","value":"6.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1865"},{"groupId":"OG001","value":"1872"}],"units":"Participants"}],"title":"Change at FU Month 24: Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.4","value":"7.9"},{"groupId":"OG001","spread":"27.9","value":"7.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1817"},{"groupId":"OG001","value":"1790"}],"units":"Participants"}],"title":"Change at FU Month 36: Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"81.9"},{"groupId":"OG001","spread":"24.1","value":"80.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2332"},{"groupId":"OG001","value":"2336"}],"units":"Participants"}],"title":"Baseline: Social"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.8","value":"-8.7"},{"groupId":"OG001","spread":"27.1","value":"-7.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2071"},{"groupId":"OG001","value":"2110"}],"units":"Participants"}],"title":"Change at Week 13: Social"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.5","value":"-2.2"},{"groupId":"OG001","spread":"26.3","value":"-0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2044"},{"groupId":"OG001","value":"2072"}],"units":"Participants"}],"title":"Change at Week 25: Social"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.2","value":"0.0"},{"groupId":"OG001","spread":"26.3","value":"1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2282"}],"units":"Participants"}],"title":"Change at EOT: Social"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.8","value":"5.0"},{"groupId":"OG001","spread":"26.7","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1910"},{"groupId":"OG001","value":"1915"}],"units":"Participants"}],"title":"Change at FU Month 18: Social"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.8","value":"5.5"},{"groupId":"OG001","spread":"26.6","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1864"},{"groupId":"OG001","value":"1868"}],"units":"Participants"}],"title":"Change at FU Month 24: Social"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.9","value":"6.6"},{"groupId":"OG001","spread":"27.3","value":"7.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1812"},{"groupId":"OG001","value":"1783"}],"units":"Participants"}],"title":"Change at FU Month 36: Social"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.6","value":"88.8"},{"groupId":"OG001","spread":"17.9","value":"87.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2334"},{"groupId":"OG001","value":"2341"}],"units":"Participants"}],"title":"Baseline: Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.5","value":"-9.1"},{"groupId":"OG001","spread":"21.4","value":"-9.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2073"},{"groupId":"OG001","value":"2115"}],"units":"Participants"}],"title":"Change at Week 13: Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.4","value":"-7.6"},{"groupId":"OG001","spread":"20.8","value":"-7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2046"},{"groupId":"OG001","value":"2076"}],"units":"Participants"}],"title":"Change at Week 25: Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.6","value":"-7.7"},{"groupId":"OG001","spread":"21.4","value":"-7.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2259"},{"groupId":"OG001","value":"2287"}],"units":"Participants"}],"title":"Change at EOT: Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"-6.1"},{"groupId":"OG001","spread":"21.2","value":"-5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1911"},{"groupId":"OG001","value":"1920"}],"units":"Participants"}],"title":"Change at FU Month 18: Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.5","value":"-6.2"},{"groupId":"OG001","spread":"21.7","value":"-5.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1865"},{"groupId":"OG001","value":"1870"}],"units":"Participants"}],"title":"Change at FU Month 24: Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.6","value":"-5.4"},{"groupId":"OG001","spread":"21.8","value":"-4.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1814"},{"groupId":"OG001","value":"1786"}],"units":"Participants"}],"title":"Change at FU Month 36: Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.4","value":"72.8"},{"groupId":"OG001","spread":"22.7","value":"71.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2332"},{"groupId":"OG001","value":"2340"}],"units":"Participants"}],"title":"Baseline: Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.2","value":"3.3"},{"groupId":"OG001","spread":"22.5","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2071"},{"groupId":"OG001","value":"2114"}],"units":"Participants"}],"title":"Change at Week 13: Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.7","value":"5.1"},{"groupId":"OG001","spread":"22.2","value":"5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2044"},{"groupId":"OG001","value":"2076"}],"units":"Participants"}],"title":"Change at Week 25: Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.2","value":"5.6"},{"groupId":"OG001","spread":"23.4","value":"6.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2257"},{"groupId":"OG001","value":"2286"}],"units":"Participants"}],"title":"Change at EOT: Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.4","value":"7.7"},{"groupId":"OG001","spread":"23.4","value":"7.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1909"},{"groupId":"OG001","value":"1918"}],"units":"Participants"}],"title":"Change at FU Month 18: Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.3","value":"7.8"},{"groupId":"OG001","spread":"24.2","value":"8.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1864"},{"groupId":"OG001","value":"1869"}],"units":"Participants"}],"title":"Change at FU Month 24: Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.8","value":"7.8"},{"groupId":"OG001","spread":"24.4","value":"8.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1812"},{"groupId":"OG001","value":"1785"}],"units":"Participants"}],"title":"Change at FU Month 36: Emotional"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2338"},{"groupId":"OG001","value":"2342"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 functioning scores were linearly transformed on a scale of 0 to 100, with a high score indicating better functioning/support. Negative change from Baseline values indicated deterioration in functioning and positive values indicated improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).","id":"OG000","title":"Pertuzumab + Trastuzumab + Chemotherapy"},{"description":"Participants received placebo matched to pertuzumab IV Q3W and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin AUC 6 (up to 900 mg).","id":"OG001","title":"Placebo + Trastuzumab + Chemotherapy"}],"paramType":"MEAN","populationDescription":"ITT population. Overall number of participants analyzed=participants evaluable for this outcome measure. Number analyzed=number of participants responding to this scale where it is considered complete as defined by the EORTC QLQ-C30 scoring manual.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36","title":"Change From Baseline in EORTC QLQ-C30 Functioning Subscale Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}